Simple combinations of 5‐FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S‐1
Authors:
Open Access
- 30 May 2006
- journal article
- early detection-and-diagnosis
- Published by Wiley in International Journal of Cancer
- Vol. 119 (8) , 1927-1933
Abstract
We evaluated the expression of 5‐FU pathway genes in prechemotherapeutic fresh frozen samples obtained from primary tumors to predict response and survival of 59 metastatic gastric cancer patients treated with S‐1 monotherapy as first line treatment. Five 5‐FU pathway genes, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP) and uridine phosphorylase (UP), were analyzed by the quantitative real‐time reverse transcriptional PCR method. Median values of each gene were selected for cut‐off values separating high and low gene expressions. In univariate analyses, low TS, high OPRT and low TP were significantly associated with a tumor shrinkage and a long survival, whereas DPD and UP gene expressions did not correlate with response and survival. Multivariate analyses revealed that independent variables were OPRT and TS for response and TS and TP for survival. When OPRT and TS were combined, a significantly increased accuracy rate of 91.5% was seen for response. Similarly, an increased hazard ratio of 10.29 was observed for survival in patients possessing low TS and low TP, compared with those with high TS or high TP. The simple combinations of 2 genes, OPRT and TS for response and TS and TP for survival, may allow identification of gastric cancer patients who will benefit from S‐1 chemotherapy.Keywords
This publication has 34 references indexed in Scilit:
- Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenaseAnnals of Oncology, 2005
- Current status and future prospects of chemotherapy for metastatic gastric cancer: a reviewGastric Cancer, 2005
- Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatmentThe Lancet Oncology, 2005
- The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5′-deoxy-5-fluorouridineEuropean Journal of Cancer, 2004
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5‐FluorouracilJapanese Journal of Cancer Research, 2000
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998
- Reduced Activity of Anabolizing Enzymes in 5‐Fluorouracil‐resistant Human Stomach Cancer CellsJapanese Journal of Cancer Research, 1996
- Assessment of response to therapy in advanced breast cancer1978
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960